O-GlcNAcylation: a pro-survival response to acute stress in the cardiovascular and central nervous systems
O-GlcNAcylation is a unique monosaccharide modification that is ubiquitously present [...]
O-GlcNAcylation is a unique monosaccharide modification that is ubiquitously present [...]
As a non-classical post-translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) [...]
Pathological TDP-43 aggregation is characteristic of several neurodegenerative diseases, including [...]
O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer's disease (AD) [...]
The dopamine system in the midbrain is essential for volitional [...]
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Huntington's disease (HD) is caused by an expanded CAG repeat [...]
[18F]MK-8553 is a high affinity, selective OGA inhibitor with properties [...]
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]